Episode Details
Back to Episodes
Daily Roundup | Capricor's Duchenne Cell Therapy Voted Down — What It Means for the Field
Published 1 month, 2 weeks ago
Description
FDA advisers recommended against Capricor's deramiocel — and the stock had already lost up to 60% before the vote. Also: Replimune falls nearly 40% as FDA reviewers call RP1's melanoma survival data uninterpretable ahead of Thursday's panel; Biogen posts $2.7 billion and cuts EPS guidance on Apellis dilution as Leqembi, Spinraza and Skyclarys beat; AstraZeneca defends its $80 billion 2030 target and GSK bets its growth plan on oncology expansion; Vertex pays AbCellera $28 million upfront for autoimmune T-cell engagers; plus ProMIS in Alzheimer's, Atea in hepatitis C, and Altimmune in alcohol use disorder.
Visit us at thepharmacloseout.com.